Zevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $25.00

Zevra Therapeutics (NASDAQ:ZVRA) had its target price boosted by research analysts at Maxim Group from $18.00 to $25.00 in a note issued to investors on Tuesday, Marketbeat reports. The brokerage presently has a “buy” rating on the stock. Maxim Group’s target price would indicate a potential upside of 231.35% from the company’s previous close.

Several other equities analysts have also recently issued reports on the stock. William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a report on Wednesday, August 14th. Canaccord Genuity Group cut their target price on Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Wednesday, September 18th. Finally, HC Wainwright upped their price target on Zevra Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, September 20th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Zevra Therapeutics currently has an average rating of “Buy” and a consensus target price of $21.00.

Zevra Therapeutics Trading Down 8.8 %

NASDAQ ZVRA opened at $7.55 on Tuesday. The company has a market cap of $397.02 million, a price-to-earnings ratio of -5.59 and a beta of 1.94. Zevra Therapeutics has a twelve month low of $3.89 and a twelve month high of $8.95. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 1.80. The business’s fifty day moving average is $7.12 and its 200 day moving average is $5.74.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The firm had revenue of $4.45 million for the quarter, compared to analyst estimates of $4.08 million. Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. During the same period in the previous year, the business posted ($0.15) earnings per share. As a group, sell-side analysts expect that Zevra Therapeutics will post -1.59 EPS for the current fiscal year.

Insider Buying and Selling at Zevra Therapeutics

In other Zevra Therapeutics news, Director John B. Bode purchased 10,000 shares of the firm’s stock in a transaction on Friday, July 12th. The stock was purchased at an average cost of $5.87 per share, for a total transaction of $58,700.00. Following the acquisition, the director now owns 30,000 shares in the company, valued at approximately $176,100. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Over the last quarter, insiders have bought 22,000 shares of company stock valued at $140,340. 2.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD acquired a new position in shares of Zevra Therapeutics during the first quarter valued at about $64,000. The Manufacturers Life Insurance Company increased its position in Zevra Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after buying an additional 2,452 shares in the last quarter. Focus Financial Network Inc. ADV acquired a new position in Zevra Therapeutics during the 4th quarter worth approximately $141,000. Virtu Financial LLC bought a new position in Zevra Therapeutics in the fourth quarter worth approximately $177,000. Finally, Jacobs Levy Equity Management Inc. grew its stake in Zevra Therapeutics by 102.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock valued at $201,000 after acquiring an additional 17,557 shares during the period. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.